3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasms
2
Multiple Myeloma
2
Melanoma
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Thyroid Neoplasms
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Polycystic Ovary Syndrome
1
Peritoneal Neoplasms
1
Pancreatic Ductal Adenocarcinoma
1
Pain
1
Monoclonal Gammopathy of Undetermined Significance
1
Magnetic Resonance Imaging
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Limited Stage Small Cell Lung Cancer
1
Kidney Neoplasms
1
Hypothyroidism
1
Hyperphagia
1
Hepatic Encephalopathy
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Goiter
1
Interventions
Paclitaxel
24
Hyperthermic Intraperitoneal Chemotherapy
24
Cisplatin
22
Oxaliplatin
17
Carboplatin
17
Fluorouracil
13
Cytoreduction Surgical Procedures
13
Bevacizumab
10
Mitomycin
9
Leucovorin
8
Doxorubicin
8
Docetaxel
6
Gemcitabine
5
130-nm albumin-bound paclitaxel
5
Surgical Procedures, Operative
4
Blood Specimen Collection
4
Albumin-Bound Paclitaxel
4
sodium thiosulfate
3
liposomal doxorubicin
3
catumaxomab
3
Taxes
3
Neoadjuvant Therapy
3
Drug Therapy
3
tremelimumab
2
relacorilant
2
pembrolizumab
2
olaparib
2
nintedanib
2
epothilone B
2
Topotecan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Peritoneal Neoplasms
×
Glucose
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts